Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc

<< Previous

Bullboard Posts

Next >>

Post by theshadow39on Apr 15, 2019 11:38pm

100 Views

Post# 29631273

Vir 1 of 4 cannabis companies with a cash burn rate to last

Thanks Redearth, I can’t wait for some real news as well. But having a pr person in a company that has not been pumped is a huge step in the right direction. 2 months ago I had never even heard of this company.

Interesting that Vir is one of 4 Canadian companies with a cash burn rate to survive the above period of time.

I will be anxiously awaiting their business expansion plans. I’m all about low grow high margin products. To start oil. I’m crossing my fingers they don’t blow the bank on a pure grow.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading